Your AI-Trained Oncology Knowledge Connection!
“With more potent agents, can we actually cure patients [with prostate cancer]? I'm not so sure about that…because of heterogeneity,” said an expert from NewYork-Presbyterian – Weill Cornell Medical Center in New York City. “So we'll see. But I think with combinations, maybe someday we're going to be able to get there.”
Theranostics may fill an unmet need for a group of patients with high-risk localized prostate cancer, but more research is needed to identify how oncology providers can integrate it with the standard treatments, according to an expert from the University of Texas MD Anderson Cancer Center.
With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Patients with advanced prostate cancer benefitted from relugolix vs leuprolide regardless of baseline testosterone level.
An expert from NYU Langone in New York City recently discussed the strengths and limitations of the oral tyrosine kinase inhibitor mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion+ metastatic non-small cell lung cancer.
The use of hypomethylating drugs such as azacitidine and decitabine improved outcomes for patients of advanced age with acute myeloid leukemia, according to findings from a recent retrospective study of real-world data.
The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.
Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.
Rezvilutamide with androgen-deprivation therapy yielded improved overall survival and radiographic progression-free survival compared with bicalutamide and androgen-deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer.
The allogeneic anti-CD19 CAR-T cell therapy CB-010 has received 2 designations from the FDA, including a fast-track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.
Atezolizumab is no longer available to treat patients with advanced or metastatic bladder cancer following the manufacturer’s decision to withdraw its U.S. indication after consulting with the FDA.
Real-world patients with stage III colon cancer who were treated in the community practice setting with modified FOLFOX6 received less oxaliplatin vs historic controls from the phase 3 MOSAIC trial.
Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.
Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.
A longer, 30-month treatment duration with bevacizumab did not improve outcomes over the standard 15-month treatment duration in patients with newly diagnosed ovarian cancer.
A complete response letter from the FDA indicated that poziotinib as a treatment for non-small cell lung cancer harboring HER2 exon 20 insertion mutations cannot be approved in its current form.
Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.
Erica C. Nakajima, MD, discussed a pooled analysis analyzing immune checkpoint inhibitors with or without chemotherapy in the frontline treatment of patients with KRAS-mutated non-small cell lung cancer and PD-L1 expression.
Ursula A. Matulonis, MD, spoke about the next steps for mirvetuximab soravtansine in the treatment of patients with folate receptor α–high platinum-resistant ovarian cancer.
From shortening treatment duration without compromising efficacy in breast and prostate cancer to improving quality of life, experts share the main takeaways from the 2022 ASTRO Annual Meeting.
Results from a phase 2 trial indicated that subgroups of patients with advanced or metastatic sarcoma may benefit from durvalumab plus tremelimumab, with data encouraging further evaluation in the population.
The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.
According to Hurvitz, the findings of trials such as DESTINY-Breast04 and TROPiCS-02 shed light on potential new therapies for breast cancer, though more research is needed to address new agents and other unmet needs.
Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.
According to an expert, more than 90% of patients with newly diagnosed transplant-ineligible multiple myeloma treated with daratumumab plus lenalidomide and dexamethasone will achieve some type of response.
Income- and race-related disparities concerning supportive therapies for hormone receptor–positive breast cancer require further study to ensure equitable care and access for all patients, according to Melanie Wain Kier, MD, MBA.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Takayuki Yoshino, MD, PhD, spoke about the benefit of panitumumab vs bevacizumab in combination with mFOLFOX6 in the frontline treatment of patients with RAS wild-type metastatic colorectal cancer.
The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
